Anne-Marie Koop

8 299 blood-derived multi-biomarker approach in pediatric patients with CHD that may contribute to the characterization of RV adaptation to abnormal loading conditions and, eventually, aims for early recognition of adverse processes in RV remodelling and guidance in decisions on treatment strategies. SOURCE OF FUNDING This study was funded in part by the Sebald fund. DISCLOSURES The University Medical Center Groningen, which employs Dr. RA de Boer has received research grants and/or fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, Novo Nordisk, and Roche. Dr. RA de Boer received speaker fees from Abbott, AstraZeneca, Novartis, and Roche. The University Medical Center Groningen contracts with Actelion, Lilly, GSK and Pfizer and received fees for steering committee and advisory board activities by Dr. RMF Berger.